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Introduction
In humans, nearly 1% of  newborns are affected by congenital heart defects (CHDs), and epidemiolog-
ical studies have suggested significant genetic contribution to the manifestation of  CHDs (1–3). While 
most CHD cases occur sporadically, some familial cases have shown Mendelian inheritance patterns (4). 
Although the more common types of  CHDs are complex disorders, mutations in single genes, such as 
NKX2-5, GATA4, and TBX1, were found to associate with rare forms of  CHDs (1, 5–7).
Collagens are major components of  the extracellular matrix; they play a key role in the induction 
of  cell differentiation and tissue morphogenesis. We elucidated the function of  IIA in IIA procolla-
gen-deficient mice, generated by deleting exon II of  Col2a1 in a hybrid genetic background (8). How-
ever, mice homozygous for the IIA-null mutation (IIA−/−) displayed a variable severity of  the congen-
ital malformations, ranging from lethal heart malformation and craniofacial defects to near-normal 
phenotypes (Supplemental Figure 1; supplemental material available online with this article; https://
doi.org/10.1172/jci.insight.98555DS1). To assess the heart defect phenotypes with different genetic 
backgrounds, three heterozygous IIA+/− mutant mouse lines enriched with C57BL/6N, 129/SvEv, and 
Incomplete penetrance of congenital heart defects (CHDs) was observed in a mouse model. We 
hypothesized that the contribution of a major genetic locus modulates the manifestation of 
the CHDs. After genome-wide linkage mapping, fine mapping, and high-throughput targeted 
sequencing, a recessive frameshift mutation of the heterogeneous nuclear ribonucleoprotein A1 
(Hnrnpa1) gene was confirmed (Hnrnpa1ct). Hnrnpa1 was expressed in both the first heart field 
(FHF) and second heart field (SHF) at the cardiac crescent stage but was only maintained in SHF 
progenitors after heart tube formation. Hnrnpa1ct/ct homozygous mutants displayed complete CHD 
penetrance, including truncated and incomplete looped heart tube at E9.5, ventricular septal defect 
(VSD) and persistent truncus arteriosus (PTA) at E13.5, and VSD and double outlet right ventricle 
at P0. Impaired development of the dorsal mesocardium and sinoatrial node progenitors was also 
observed. Loss of Hnrnpa1 expression leads to dysregulation of cardiac transcription networks 
and multiple signaling pathways, including BMP, FGF, and Notch in the SHF. Finally, two rare 
heterozygous mutations of HNRNPA1 were detected in human CHDs. These findings suggest a role 
of Hnrnpa1 in embryonic heart development in mice and humans.
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ICR background were established, and the inheritance of  the CHD/death phenotype was evaluated by 
the Mendelian ratio of  the IIA genotypes in IIA+/− × IIA+/− crosses of  different genetic backgrounds. 
However, among the IIA+/− mutant mouse lines, only the IIA-null population from C57-IIA+/− × C57-
IIA+/− crosses was significantly underrepresented, whereas ICR-IIA+/− × C57-IIA+/− crosses produced 
a normal Mendelian ratio (Supplemental Table 1). Thus, we hypothesized that the incomplete pene-
trance of  CHD phenotypes was due to the involvement of  an additional CHD-causing genetic factor 
rather than a random shift of  the phenotypes. The CHD-causing genetic locus might be a mutant gene 
that was created during the targeted disruption of  Col2a1 and was only successfully fixed in the con-
genic C57-IIA+/− mouse line. The suspected genetic lethality may therefore be inherited in a recessive 
manner and linked with the mutant Col2a1 allele, as the locus was nonpathogenic in C57-IIA+/− het-
erozygotes. The IIA−/− genotype alone was not sufficient for the manifestation of  CHD phenotypes.
The CHD candidate locus was then mapped on chromosome 15qF3, which is approximately 9 cM 
away from the Col2a1 locus. The cardiac phenotype of  this particular line was lost after crossing over with 
the allele from C57BL/6N, 129/SvEv, or ICR, further supporting a recessive inheritance model. Fine map-
ping using a congenic set of  C57-IIA−/− embryos narrowed down the candidate region to 1.2 Mb (chr15 
from 102.29–103.49 Mb) and confirmed a recessive Mendelian inheritance pattern for this new genetic 
locus. A frameshift CT deletion in exon 5 of  the heterogeneous nuclear ribonucleoprotein A1 (Hnrnpa1) 
gene was detected by targeted next-generation sequencing (NGS) of  the candidate region and confirmed by 
Sanger sequencing (we refer to the mutant allele as Hnrnpa1ct). Further experiments demonstrate that the 
Hnrnpa1ct/ct mutation alone is sufficient to cause heart defects at different developmental stages, including 
E9.5, E13.5, and at birth (Table 1).
hnRNP A1, a member of  the hnRNP A/B subfamily, is reported to take part in pre-mRNA alterna-
tive splicing, mRNA export and turnover, translation, miRNA processing, and the regulation of  telomeres 
(9–13). A recent study revealed that, during smooth muscle differentiation, hnRNP A1 directly binds to 
the promoters of  MEF2c, SRF, and myocardin (Myocd) to activate their transcription (14). MEF2c is a tran-
scription factor required for proper outflow tract (OFT) alignment, regulation of  anterior heart field (AHF), 
and cardiomyocyte differentiation (15); it is associated with congenital OFT defects in human patients (16). 
Myocardin forms a complex with SRF to activate the expression of  downstream cardiac genes (17). In 
vitro experiments show that hnRNP A1 promotes the alternative translation of  FGF2 at 4 IRES-dependent 
initiation sites (18). Isoform-specific ablation of  FGF2 in mice has been shown to cause different heart 
defects in a sex-dependent manner (19). Previous reports have proposed that FGF2 may drive specification 
of  cardiogenic lineage in the anterior lateral plate mesoderm (ALPM) (20, 21), promote proliferation of  
cardiomyocytes and vascular formation (22), and control the differentiation of  resident cardiac precursors 
into cardiomyocytes in neonatal hearts (23). According to these results, we propose that Hnrnpa1 plays an 
essential role during cardiac development, and we are the first to our knowledge to demonstrate that muta-
tions in Hnrnpa1 cause heart defects during early cardiac developmental stages.
Results
Identification of  Hnrnpa1 as an independent disease gene during cardiac development. A de novo mutation 
was generated during the targeted disruption of  exon 2 of  the Col2a1 gene. We hypothesized that a 
CHD-causing genetic locus already existed in the IIA-null mouse line with hybrid genetic background 
and generated a mapping panel for genome-wide linkage analysis in the F2 generation of  mice from 
the C57-IIA+/− × ICR-IIA+/− crosses. A total of  117 SNPs with alleles differentiating C57BL/6J from 
Table 1. Heart defects in homozygous frameshift CT deletion in Hnrnpa1 in mice
Heart defects Normal Normal Total no.
IIA+/+; Hnrnpa1ct/ct IIA+/+; Hnrnpa1+/ct IIA+/+; Hnrnpa1+/+
E9.5 74 137 57 268
E13.5 3 15 19 37
P0 (at birth) 2 56 37 95
Embryos/mice were obtained from crosses of IIA+/+, Hnrnpa1+/ct × IIA+/+, Hnrnpa1+/ct mice at E9.5, E13.5, and P0. The heart defects only can be observed in 
homozygous deletion mutants (Hnrnpa1ct/ct) with recessive inheritance model.
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ICR at a density of  20 cM were selected from the genome. Seventy-two P0 newborns from 8 litters with 
11 CHD cases and thirty-eight E9.5 embryos from 3 litters with 6 CHD cases were genotyped. Using 
Simwalk2, which contains BLOCK statistics and is the most powerful method to detect linkage in a 
recessive model, a significant linkage on chromosome 15 at 60 cM was detected with –log(P) = 4 in 
nonparametric linkage (NPL) ALL statistics and –log(P) > 3 in BLOCK statistics in the recessive model 
(Figure 1A and Supplemental Figures 2 and 3). With increased marker density in this region, the data 
sets showed a genome-wide significant NPL, with –log(P) = 4 in the NPL ALL score for both E9.5 and 
P0. Moreover, the NPL result suggests that the defects in the two developmental stages were possibly 
due to the same genetic variant and, thus, originated from the same developmental process. The data 
sets of  the two stages were combined to perform transmission disequilibrium test (TDT) analysis using 
40 markers. Significant association (P = 9.634 × 10–7) with the phenotype was found starting from 98.95 
Mb (Figure 1B). We hypothesized that the genetic locus for CHD is located beyond 98.95 Mb toward 
the end of  chromosome 15, where the IIA-null alleles from C57-IIA+/− mice are predominantly trans-
mitted to affected individuals. To better understand the transmission pattern of  the segment beyond 
the breakpoint, we traced the transmission of  the haplotypes in the affected litters in a subset of  the 
mapping pedigrees. To avoid the phasing problem, we selected 18 SNPs that were homozygous for one 
of  the F0 parents but heterozygous for another (Supplemental Table 2). The C57-IIA+/− mutant mouse 
line was found to be very heterogeneous in this region. Assuming the CHD-causing haplotype (shown 
in red in Figure 1C) (referred to herein as 154.4) is linked to the IIA locus, the white bar (as shown in 
Figure 1C) should be inherited from C57BL/6N, acquired from backcrossing. The ICR-IIA+/− line, on 
the other hand, is very homogenous (green bar, Figure 1C). There is one SNP (rs6284372) at 99.3Mb, 
however, that was found to be homozygous in the 154.4 haplotype but heterozygous in ICR. The hap-
lotype information is mainly inferred from this SNP. The 154.4/154.4 homozygous genotype was pre-
dominantly transmitted to affected individuals (Figure 1C). Given that some of  the unaffected mutants 
also carried the same haplotype, the causative mutation was probably more distant and estimated to be 
approximately 9 cM away from the region, which spanned across Col2a1 and was inherited from the 
C57-IIA+/− mutant mouse line. Consistent with our hypothesis, this haplotype configuration did not 
match with that of  our C57BL/6N wild-type stock or C57BL/6J in the NCBI database. The config-
uration matched that of  our 129/SvEv wild-type stock and 129S1/SvImJ from the Mouse Phenome 
database (Supplemental Figure 4). Since we did not observe any cardiac abnormalities in the mice with 
genotype of  129-IIA−/−  in embryonic or postnatal stages (Supplemental Table 1), and assuming that the 
ES cell used for generating the IIA-null mutant was indeed a hybrid of  129S1/SvImJ and 129X1/SvJ, 
we hypothesized that this segment of  DNA contained a mutation that caused CHD, which was generat-
ed during the targeted disruption of  Col2a1 and cosegregated with the IIA-null locus. This genetic locus 
was fixed in the C57-IIA+/− mutant mouse line during backcrosses.
Establishment of  an IIA wild-type CHD mouse line by identifying a recombinant of  Col2a1 and rs3218302 loci. 
To further define whether the IIA-null allele contributed to the occurrence of  CHD phenotype, we generat-
ed more C57-IIA−/− embryos and conducted fine mapping using additional SNPs. Supplemental Figure 1G 
shows the prevalence of  CHD in each litter collected from C57-IIA+/− × C57-IIA+/− crosses We genotyped 
8 affected and 8 unaffected C57-IIA−/− embryos from the 6 litters collected in the previous analysis. The 6 
litters consisted of  2 litters with 100% penetrance for CHD, 2 litters with 0%, and 2 litters with 50%, pro-
viding us with a comprehensive and representative set of  observations. The embryos were genotyped for 
18 markers of  the original mapping panel, and rs32183020, which is approximately 9 cM away from the 
Col2a1 locus, was used to mark the end of  the candidate region. Their genotype configurations are summa-
rized in Figure 1C. Two important features were noted. First, Col2a1 was indeed flanked by 129S1/SvImJ 
genetic material. Second, rs32183020 was able to differentiate the affected and unaffected CHD C57-IIA−/− 
mutants, where all CHD C57-IIA−/− mutants harbored a homozygous “CC” genotype of  rs32183020, and 
all non-CHD C57-IIA−/− mutants carried at least one copy of  the “T” allele of  rs32183020 from C57BL/6J. 
This result not only provided independent confirmation of  our linkage analysis, but also explained why the 
incomplete penetrance was previously observed in C57-IIA−/− mice. Finally, we narrowed down the candi-
date region to 1.2 Mb, with 43 transcripts encoded by 34 genes and 4 miRNAs.
With the identification of  the “C” allele of  rs32183020, which was strongly associated with the CHD 
mutant allele, we selected a recombinant mouse carrying the wild-type genotype of  IIA and a heterozy-
gous “CT” at rs32183020 from the C57-IIA+/− × C57-IIA+/− crosses. The selected recombinant mouse was 
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crossed back to the C57BL/6N wild-type mouse to establish a mouse line that only contained the CHD 
mutant allele on chromosome 15 of  the wild-type IIA.
A frameshift mutation of  the Hnrnpa1 gene causes the CHD phenotype. We performed high-throughput tar-
geted sequencing to identify a variant associated with CHD. The heterozygous (CT genotype) rs32183020 
mouse was selected, and DNA was isolated for sequencing. Custom probes (Roche NimbleGen) were 
designed to target the 1.2-Mb candidate locus (chr15: 102.29–103.49 Mb) and were selected using the 
Figure 1. Identification of a de novo CT deletion in Hnrnpa1. (A) Chromosome 15–linked congenital heart defect (CHD) locus. The x axis represents the 
relative location of markers on a chromosome, and the y axis represents the –log(P) for nonparametric linkage–ALL (NPL-ALL) scores and BLOCK recessive 
scores. (B) Transmission disequilibrium test (TDT) for the combined data set from E9.5 and P0. We genotyped 40 more SNP markers for the region of 
chr15:90.7–100.6 Mb. Significant association with the heart defect phenotype was found starting from chr15:98.95 Mb, consistent with the NPL analysis in 
the embryonic lethality data set. We hypothesized the new CHD locus should be located beyond 98.95 Mb, where alleles from the C57BL/6N mutant were 
first shown to be predominately transmitted to affected individuals. We defined this segment, which independently assorted with the IIA genotype, as a 
breakpoint between Col2a1 and the new CHD locus. The breakpoint was shown to be flanked by markers rs8277842 at 98.6 Mb and rs3708604 at 98.95 Mb 
on chromosome 15. The green arrow pointing to the left indicates the position of Col2a1 and the blue arrow pointing to the right indicates the breakpoint. 
For both A and B, P < 0.001 was considered as significant. (C) Haplotype analysis in affected litters. The same region of the TDT analysis presented in 
chr15:90.8–100.6 Mb is shown. The haplotype information (154.4) is mainly inferred from rs6284372. In this pedigree, there are 8 F1, all bearing a hetero-
zygous configuration for this segment. F2 collected from intercrossing F1 provide 3 main haplotypes: 154.4/154.4, 154.4/ICR-C14, and ICR-C14/ICR-C14. 
Among 53 individuals in F2, all 11 affected individuals was found to be carrying the 154.4/154.4 haplotype; while the unaffected individuals have a distribu-
tion of 5:24:13 for the 3 mentioned haplotype configurations, respectively. Markers do not appear to segregate in chr15:90.8–98.6 Mb, probably due to our 
selection of the IIA-null allele for a procollagen IIA–deficient mutant mouse line. Therefore, the haplotype for this region was inferred with an assumption 
that no recombination happened in the region with the pedigree under study. (D) Targeted sequencing of the 1.2-Mb candidate region detected a 2-base 
deletion in Hnrnpa1 gene. A screen shot from the IGV browser shows the deletion of CT in Hrnrnpa1 in a heterozygous mouse. (E) Sanger sequencing con-
firmed the presence of CT deletion in Hnrnpa1.
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NimbleGen 2.1 M-probe; the captured fragments were sequenced at an average of  97 times with paired-end 
90-bp reads by using NGS. We generated a sequence length of  184.4 Mb with 1.4% duplication rate. 96% 
of  the target region was covered.
We used SAMtools and default filtering parameters to obtain the variants. Twenty-three SNPs and 
twenty-eight indels were detected compared with the reference, of  which eight SNPs and sixteen indels 
were also observed in dbSNP128. Among the remaining variants, the only exonic variant led to a con-
fidently predicted loss of  function of  Hnrnpa1, and a 2-base deletion (i.e., c.539_540del; p.180_180del, 
NM_001039129 in Hnrnpa1) was annotated by both RefSeq and UCSC gene annotation (Figure 1D). 
Moreover, we confirmed the same variants by Sanger sequencing (Figure 1E).
Hnrnpa1ct/ct mutant mice display complete penetrance of  CHDs at multiple cardiac developmental stages. To further 
confirm the suspected role of  Hnrnpa1 in the pathogenesis of  CHDs, we used the Hnrnpa1+/ct heterozygotes for 
crosses. In the following text, IIA+/+ is included in all genotypes. We collected 79 Hnrnpa1ct/ct, 208 Hnrnpa1+/ct, 
and 113 Hnrnpa1+/+ mice at different developmental stages (Table 1). At E9.5, the distribution of  3 genotypes 
was consistent with Mendelian law. In Hnrnpa1+/ct heterozygotes, heart tube morphology was normal at E9.5, 
similar to that of  wild-type littermate controls (Figure 2A). However, truncated and incomplete looped heart 
tubes with hypomorphic OFTs and right ventricles were only observed in Hnrnpa1ct/ct homozygotes (Fisher’s 
exact test: P = 4.7 × 10–68; Figure 2A). Three Hnrnpa1ct/ct homozygotes were also collected at E13.5, with 
marked retarded growth. Histological analysis revealed normal anatomy in both wild-type littermate con-
trols and Hnrnpa1+/ct heterozygotes, whereas all 3 Hnrnpa1ct/ct homozygotes displayed ventricular septal defect 
(VSD) and persistent truncus arteriosus (PTA), which was caused by complete failure of  OFT septation (Fig-
Figure 2. Hnrnpa1ct/ct mutant mice display severe 
congenital cardiac malformations at E9.5 and 
E13.5. Hearts from 5 wild-type littermate controls, 5 
Hnrnpa1+/ct heterozygous mutants, and 3 Hnrnpa1ct/ct 
homozygous mutants were sectioned and stained with 
hematoxylin and eosin. (A) A truncated and incomplete 
looped heart tube in Hnrnpa1ct/ct homozygous mutants 
at E9.5. Scale bar: 500 μm. Original magnification, ×5.1. 
(B) The E13.5 Hnrnpa1ct/ct homozygous mutant heart 
with PTA and VSD. RA, right atrium; LA, left atrium; 
RV, right ventricle; LV, left ventricle; AO, aorta; PA, 
pulmonary artery; IVS, interventricular septum; PTA, 
persistent truncus arteriosus; VSD, ventricular septal 
defect. Scale bar: 2 mm.
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ure 2B). At P0, a substantial underrepresentation of  the Hnrnpa1ct/ct homozygotes was observed, indicating 
embryonic lethality. The ratio between wild-type and heterozygous mutant P0 mice approximated the expect-
ed value according to Mendelian law. The P0 distribution is similar as that in a recent report (24). The two P0 
Hnrnpa1ct/ct homozygotes displayed smaller body size and truncated head, compared with wild-type littermate 
controls and Hnrnpa1+/ct heterozygotes (Supplemental Figure 5). According to optical projection tomogra-
phy (OPT) analyses, VSD was observed in one Hnrnpa1ct/ct homozygote, while double outlet right ventricle 
(DORV) was detected in another one (Supplemental Figure 5). CHDs were also only observed in Hnrnpa1ct/ct 
homozygous mutant newborns (Fisher’s exact test: P = 2.2 × 10–4). All these results demonstrate the Hnrnpa1ct/ct 
homozygous mutation alone is sufficient to cause CHDs in our mouse model.
Hnrnpa1 is expressed in both the first heart field and second heart field cardiac lineages at the cardiac crescent 
stage but is maintained only in second heart field progenitors after heart tube formation. The cardiac malformations 
exhibited in Hnrnpa1ct/ct homozygous mutant mice led us to investigate the role of  Hnrnpa1 during cardiac 
development. We performed whole-mount in situ hybridization on wild-type embryos from E7.0–E9.5 
using riboprobe complementary for the 3′ UTR region of  Hnrnpa1 mRNA (Figure 3). We first used this 
riboprobe to hybridize E9.5 wild-type, Hnrnpa1+/ct, and Hnrnpa1ct/ct embryos from the same litter. No signal 
was detected in the Hnrnpa1ct/ct homozygous mutants, which demonstrated loss of  Hnrnpa1 transcripts and 
the specificity of  this riboprobe (Supplemental Figure 6). Isl1 was stained as an indicator for the SHF, while 
Nkx2.5 was also stained to indicate both first heart field (FHF) and second heart field (SHF) cardiac progen-
itors. In the pre–cardiac crescent stage (Figure 3, A and B), expression of  Hnrnpa1 mRNA was detected in 
the pre–cardiac ALPM. In the ensuing cardiac crescent stage, Hnrnpa1 mRNA was expressed in both the 
FHF and SHF, from which the myocardial cells and cardiac progenitors in the splanchnic mesoderm are 
derived, respectively, compared with the expression patterns of  Isl1 and Nkx2.5 (Figure 3, C–E). After heart 
tube formation, while a strong expression of  Hnrnpa1 was maintained in the splanchnic mesoderm, which 
was partially overlapped with the Isl1-expressing domain, the expression of  Hnrnpa1 was almost lost in the 
Nkx2.5-expressing differentiated myocardium (Figure 3, F–H). Following with the initiation of  the cardiac 
looping process, Hnrnpa1 continued to be strongly expressed in the splanchnic mesoderm of  the dorsal peri-
cardial wall, spanning from the distal OFT to the sinus venosus, but was absent in the myocardium of  the 
looped heart tube. The strongest expression was detected in the left and right lateral sides of  the splanchnic 
mesoderm (Figure 3I). At E9.5, the Hnrnpa1-expressing domain in the splanchnic mesoderm overlapped 
with the region of  the SHF.
Hnrnpa1ct/ct mutation leads to loss of  Hnrnpa1 expression and dysregulation of  both SHF- and heart tube–specific 
cardiac genes at E9.5. The 2-base deletion in Hnrnpa1 in mice was predicted to cause a frameshift mutation and 
to stop of  the translation early, leading to the nonsense-mediated decay of  the transcript. We quantified the 
expression of  Hnrnpa1 mRNA in mutants of  Hnrnpa1 and discovered that E9.5 homozygous mutants (Hnrn-
pa1ct/ct) displayed only about 5.86% of the expression level compared with wild-type embryos, whereas the 
relative expression of  heterozygous whole embryos (Hnrnpa1+/ct) comprised about 42.7% of the expression, as 
measured by quantitative RT-PCR (qRT-PCR) (Figure 4A). This result is consistent with the previous whole-
mount in situ hybridization analysis (Supplemental Figure 6). Western blot analysis was also performed for all 
3 genotypes at E9.5. The hnRNP A1 protein was not examined in Hnrnpa1ct/ct mutants, whereas only 45.7% 
of hnRNP A1 expression was detected in Hnrnpa1+/ct mutants compared with wide-type littermate controls 
(Figure 4B). The 2-base deletion leads to loss of  Hnrnpa1 in both mRNA and protein levels.
The pharyngeal tissues (SHF) or heart tubes of  E9.5 embryos were isolated separately and used to 
examine the transcription level of  SHF- or heart tube–specific cardiac genes by qRT-PCR, respectively 
(Supplemental Figure 7). For the SHF lineage, we analyzed the expression levels of  two bone morpho-
genetic protein (BMP) type I receptors, Acvr1 and Bmpr1a; two kinds of  fibroblast growth factor (FGF) 
Figure 3. Whole-mount in situ analysis of wild-type embryos stained for Hnrnpa1 mRNA at different embryonic days. Wild-type embryos were 
stained for Hnrnpa1 mRNA, and corresponding sections are shown from arterial pole to venous pole. At E8 and E8.25, staining for Isl1 and Nkx2.5 was 
also performed. Isl1 labels SHF cardiac progenitors, whereas Nkx2.5 labels both the FHF and SHF lineages. At each stage, results from 1 of 3 repre-
sentative experiments are displayed. (A) E7; (B) E7.5; (C–E) E8 (2 somite pairs); (F–H) E8.25 (6 somite pairs); and (I) E9.5 (20 somite pairs). (A and B) 
Expression of Hnrnpa1 in the pre–cardiac crescent stages. Hnrnpa1 mRNA is detected in the ALPM (short arrow). (C) During the cardiac crescent stage, 
Hnrnpa1 mRNA is expressed in both differentiated myocardium (thin long arrow) and splanchnic mesoderm (wide long arrow). (F) After the forma-
tion of primitive heart tube, Hnrnpa1 mRNA maintains its strong expression in the splanchnic mesoderm but with much lower expression level in the 
differentiated myocardium. (I) In E9.5 wild-type embryo, Hnrnpa1 mRNA continues to be strongly expressed in the splanchnic mesoderm but not in the 
looped heart tube. FHF, first heart field; SHF, second heart field. Scale bar: 100 μm.
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ligands, Fgf8 and Fgf10; Notch ligand Jagged1 (Jag1); and cardiac transcription factors, including Isl1, Mef2c, 
Nkx2.5, and Tbx1. All of  these genes have been confirmed to regulate development of  the SHF. In the heart 
tube, we also investigated the expression levels of  Mef2c, Mlc2a, Mlc2v, Myocd, Nkx2.5, and SRF, as these 
genes played important roles during cardiomyocytes differentiation. The mRNA levels of  several SHF car-
diac markers, including Acvr1, Bmpr1a, Fgf8, Isl1, Jag1, Nkx2.5, and Tbx1 decreased significantly in the 
pharyngeal region of  Hnrnpa1ct/ct mutants. However, no significant difference in Mlc2a, Mlc2v, Myocd, and 
SRF transcripts was detected in the Hnrnpa1ct/ct mutant heart tube. The transcripts of  Nkx2.5 reduced signifi-
cantly in the pharyngeal region of  Hnrnpa1ct/ct mutants but not in the heart tube. No significant change in 
Mef2c expression was detected in both the SHF and the heart tube (Figure 4C). These results demonstrate 
Figure 4. Expression of Hnrnpa1 and relative cardiac genes in Hnrnpa1ct/ct mutant embryos at E9.5. GAPDH was used as the internal control for qRT-PCR, 
and β-Actin was used as the loading control for Western blot, respectively. (A) qRT-PCR results for E9.5 embryos. The Hnrnpa1 mRNA level in all 3 genotypes 
is shown. Six wild-type littermate controls, nine heterozygous mutants, and eight homozygous mutants were used. (B) Three wild-type littermate controls, 
three homozygous mutants, and four heterozygous mutants were used for Western blot analysis. (C) Total RNA was extracted from isolated pharyngeal 
region or heart tube respectively at E9.5. qRT-PCR was performed to monitor the expression of both the second heart field (SHF) and heart tube–specific car-
diac genes. The number of Hnrnpa1+/+, Hnrnpa1+/ct, and Hnrnpa1ct/ct embryos in the SHF: 8, 5, and 9 for Fgf8, Fgf10, Isl1, Mef2c, and Tbx1; 8, 5, and 8 for Nkx2.5; 
8, 6, and 9 for Acvr1, Bmpr1a, and Jag1, respectively. The number of Hnrnpa1+/+, Hnrnpa1+/ct, and Hnrnpa1ct/ct embryos in the heart tube: 8, 8, and 9 for Mlc2a, 
Mlc2v, and Nkx2.5; 11, 9, and 9 for Mef2c; 11, 11, and 9 for Myocd and SRF, respectively. The values represent mean ± SD in independent samples. **P < 0.01, 
***P < 0.001, ****P < 0.0001 by unpaired 2-tailed t tests with Bonferroni correction.
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that this Hnrnpa1ct/ct mutation leads to dysregulation of  a series of  SHF-specific cardiac genes, which should 
be responsible for cardiac looping defects exhibited in the Hnrnpa1ct/ct mutants at E9.5.
Altered expression pattern of  Nkx2.5 and Isl1 demonstrates cardiac defects associated with both FHF and SHF 
lineages in Hnrnpa1ct/ct homozygous mutants. The expression pattern of  Hnrnpa1 is reminiscent of  that of  other 
essential genes during cardiac development. The VSD, PTA, and DORV displayed in the Hnrnpa1ct/ct homo-
zygous mutants suggest that Hnrnpa1 may be involved in the proliferation/migration of  cardiac progeni-
tors. To investigate the effect of  Hnrnpa1 deletion on other cardiac developmental genes, whole-mount in 
situ hybridization was performed on E8–E9.5 embryos to analyze the expression pattern of  Nkx2.5 and Isl1.
Nkx2.5 is reportedly expressed in both the FHF and SHF. In the heart tube, Nkx2.5 can either coop-
erate with Tbx5 or work with Tbx2 and Tbx3 to promote or suppress the differentiation of  myocardium, 
respectively (25–27). Recent work also shows that Nkx2.5 is essential in coordinating the proliferation 
and differentiation in the SHF (28, 29). Whole-mount in situ analysis demonstrated that CT deletion 
in Hnrnpa1 alters the expression pattern of  Nkx2.5 mRNA at several critical developmental time points 
(Figure 5). At the cardiac crescent stage (3 somite pairs), there was a marked loss of  Nkx2.5-expressing 
myocardium in the cardiac crescent (FHF lineage) of  the Hnrnpa1ct/ct homozygous mutants (Figure 5, C 
and D, thin long arrow). Reduced expression of  Nkx2.5 mRNA was also detected in the medial splanch-
nic mesoderm (SHF lineage) (Figure 5, C and D, wide long arrow) as well as in the ventral foregut 
endoderm (Figure 5, C and D, short arrow). After the initiation of  cardiac looping (9 somite pairs), a 
lower expression level of  Nkx2.5 mRNA was detected in both the OFT and sinus venosus myocardium 
(Figure 5, G and H, thin long arrow) as well as in the ventral foregut endoderm at the arterial pole (Fig-
ure 5, G and H, short arrow). Hnrnpa1ct/ct homozygous mutant hearts were truncated and resembled the 
primitive linear heart tube, with posterior extension of  the Nkx2.5-expressing sinus horns (Figure 5, E 
and F). By late E9.5 (25 somite pairs), the Hnrnpa1ct/ct mutant heart was incompletely compacted, with 
enlarged atria (Figure 5, I and J). The expression of  Nkx2.5 in the splanchnic mesoderm was confined 
to the more medial region (Figure 5, K and L, wide long arrow), together with a reduced level in the 
ventral foregut endoderm (Figure 5, K and L, short arrow). These results suggest that Hnrnpa1 may be 
required for the maintenance or proliferation of  Nkx2.5-positive cardiac progenitors derived from both 
the FHF and SHF lineages.
We next examined Isl1, which marks the SHF lineage (30, 31). Isl1 can either cooperate with Mesp1 
to induce the specification of  earliest cardiac progenitors or promote proliferation and maintain dif-
ferentiation delay in the SHF. Isl1 also coordinates several signaling pathways, including the canonical 
WNT, FGF, and BMP pathways (31–34). Whole-mount in situ analysis of  Isl1 mRNA showed severe 
SHF associated defects in the Hnrnpa1ct/ct homozygous mutants (Figure 6, A–L). At the cardiac crescent 
stage (2 somite pairs), the Isl1-expressing domain in the medial splanchnic mesoderm was restricted to a 
more anterior region along the body axis compared with the wild-type embryos (Figure 6, A and B). For-
mation of  pharyngeal mesoderm (SHF lineage) (Figure 6, C and D, wide long arrow) and foregut endo-
derm (Figure 6, C and D, short arrow) were also impaired. Further results showed that Isl1 expression in 
both splanchnic mesoderm (Figure 6, G and H, wide long arrow) and ventral foregut endoderm (Figure 
6, G and H, short arrow) was progressively lost after the initiation of  cardiac looping morphogenesis in 
the E8.5 (9 somite pairs) embryos and was more marked in the arterial pole. At E9.5 (25 somite pairs), 
Isl1 expression was markedly reduced throughout the dorsal pericardial wall spanning from the OFT 
to the sinus venosus in both splanchnic mesoderm (Figure 6, K and L, wide long arrow) and foregut 
endoderm (Figure 6, K and L, short arrow). By E9.5, Isl1 was expressed in a small population of  cells in 
the right lateral junction between the atria and sinus horn to initiate the specification of  sinoatrial node 
Figure 5. In situ analysis for Nkx2.5 demonstrates that Hnrnpa1ct/ct mutation leads to severe defects in both the FHF and SHF lineages. Detec-
tion of Nkx2.5 mRNA by whole-mount in situ hybridization in both wild-type littermate controls and Hnrnpa1ct/ct homozygous mutants. Wild-type 
littermates and homozygous mutants are indicated by +/+ and ct/ct, respectively. Sections shown below are from arterial pole to venous pole. At 
each stage, results from 1 of 3 representative experiments are displayed. (A–D) E8 (3 somite pairs) embryos are shown in the ventral view, with cor-
responding sections. (E–H) E8.5 (9 somite pairs) embryos are shown from the right, ventral, and left, with sections from anterior to posterior poles. 
(I–L) E9.5 (25 somite pairs) embryos are shown from right to left lateral views, with corresponding sections. The arrows in each photo represent the 
regions with lower Nkx2.5 mRNA levels in homozygous mutants. A markedly changed expression pattern of Nkx2.5 was detected in differentiated 
myocardium (thin long arrow), foregut endoderm (short arrow), and splanchnic mesoderm (SHF, wide long arrow). FHF, first heart field; SHF, second 
heart field. Scale bar: 100 μm.
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(SAN) progenitors (35). Such expression was absent in the Hnrnpa1ct/ct mutants, indicating the impaired 
development of  the SAN (Figure 6, I and J). Moreover, the expression of  Isl1 decreased substantially in 
the dorsal mesocardium (DM) (Figure 6, M and N), which might interrupt the development of  dorsal 
mesenchymal protrusion (DMP) and atrioventricular septum in later stages (36).
Nkx2.5 and Isl1 play an important role to coordinate the specification, maintenance, and proliferation 
of  cardiac progenitors. The altered expression pattern of  Nkx2.5 and Isl1 in cardiac progenitors suggests 
that the severe congenital cardiac defects associated with Hnrnpa1ct/ct mutation may be mediated by genetic 
regulation of  Nkx2.5 and Isl1.
KO of  Hnrnpa1 prevents the differentiation of  mESCs into cardiomyocytes in vitro. Hnrnpa1 KO 1 and 
KO 2 mouse embryonic stem cells (mESCs) were generated by CRISPR/Cas9 deletion of  different 
fragments of  exon 6 of  Hnrnpa1 in Nkx2.5-EGFP-mESCs (Figure 7A). A single mESC was seeded into 
ultra-low attachment plates, and formation of  embryonic bodies (EBs) was observed 2–3 days later. 
Between day 3 and day 5, EBs from Nkx2.5-EGFP-mESCs formed tight clusters, whereas EBs in Hnrn-
pa1 KO 1 and KO 2 groups were loosely aggregated (Figure 7B). At the end of  day 6, EBs in all groups 
were transferred into a new fibronectin-coated plate separately to initiate cardiomyocytes differentia-
tion. Almost all EBs in the Nkx2.5-EGFP-mESC group attached to the plate and formed outgrowths 
between day 6 and day 9. In contrast, EBs of  Hnrnpa1 KO 1 and KO 2 mESCs attached and outgrew 
poorly at a slower rate, with obviously elevated cell death. Only very few living cells could be observed 
in KO 1 and KO 2 groups at day 9 (Figure 7B). mESCs in all groups were collected at day 7 to assess 
the status of  cardiomyocytes differentiation. Flow cytometry analysis demonstrated that significantly 
fewer Nkx2.5-EGFP–positive cells were present in Hnrnpa1 KO 1 and KO 2 culture compared with the 
Nkx2.5-EGFP-mESC group (Figure 7C and Supplemental Figure 8). All mESCs in KO 1 and KO 2 
groups died after day 9.
Heterozygous mutations in HNRNPA1 in human CHDs. We sequenced human HNRNPA1 in two sam-
ple sets containing 273 Chinese CHD trio probands and 225 Pakistani probands with CHD (Sup-
plemental Tables 3 and 4). A rare missense variant (NM_031157.2, c. G847A; NP_112420.1, p. 
G283R, rs375259222) was identified in a 5-month-old boy (ID X122) with VSD, a history of  patent 
foramen ovale, moderate mitral regurgitation, and pulmonary hypertension. A novel indel variant 
(NM_031157.2, c. 607-609 del GGT; NP_112420.1, p. 203 del G) in a 1-year-old boy (ID X102) with 
VSD (infracristal L–R) was also detected. We also sequenced the gene of  available parents. The patient 
(ID X122) with the p.G283R variant (rs375259222) inherited this variant from his mother, and clinical 
information about his mother was not available. The patient (ID X102) with the p.203 del G harbored 
a de novo deletion (Figure 8A).
We considered how the variants potentially affect the protein. rs375259222 (G283R) located after the 
RRM superfamily domain with a nonpolar amino acid glycine was replaced by a polar positive amino acid 
arginine at position 283. The de novo mutation of  p. 203 del Gly is located in the poly-Gly region that is 
important for protein structure and not near the C-terminus. Gly203 and Gly283 are both highly conserved 
among all species (human, cattle, pig, mice, chimpanzee, monkey, and rat; Figure 8B). Mutation Taster, 
PolyPhen 2, FATHMM, and other 4 programs predicted the variant (G283R) of  rs375259222 as possibly 
damaging (Table 2).
These two variants were not found in NCBI dbSNP (version 144), in the 1000 genome project database, 
or in our 300 normal controls; rs375259222 is in the EVA_EXAC database (2015 version), with 7 allele 
counts among the 103,578 total allele counts, indicating that it is a very rare allele in populations. These 7 
allele counts are all found in Asians, and it is most likely a recent rare variant.
Figure 6. Altered expression pattern of Isl1 shows SHF-related defects in Hnrnpa1ct/ct mutants. Whole-mount in situ hybridization analysis of Isl1 mRNA 
in Hnrnpa1ct/ct homozygous mutants and wild-type littermate controls. Wild-type embryos and Hnrnpa1 homozygous mutants are labeled by +/+ and ct/ct, 
respectively. At each stage, results from 1 of 3 representative experiments are displayed. (A, B, E, F, I, and J) Whole-mount in situ hybridization analysis for 
embryos at E8 (2 somite pairs), E8.5 (9 somite pairs), and E9.5 (25 somite pairs). (I and J) The expression of Isl1 in a small subset of SAN progenitors is lost 
in Hnrnpa1ct/ct homozygous mutants. (C, D, G, H, K, and L) Corresponding sections are shown below at different levels from arterial pole to venous pole. (C 
and D) Sections at the cardiac crescent stage (E8). (G and H) Sections are shown at OFT region, middle portion of the heart tube, and sinus venosus (E8.5). 
(K and L) Sections are shown from OFT to sinus venous at E9.5. The expression of Isl1 decreases markedly in the truncated DM of Hnrnpa1ct/ct homozygous 
mutants. (M and N) Decreased Isl1 mRNA or Isl1-expressing cardiac progenitors can be found in both splanchnic mesoderm (SHF, wide long arrow) and 
ventral foregut endoderm (short arrow). DM, dorsal mesocardium; OFT, outflow tract; SAN, sinoatrial node; SHF, second heart field. Scale bar: 100 μm.
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Discussion
IIA−/− mice displayed complex congenital malformations, ranging from heart malformations and head 
truncation, resulting in prenatal lethality to near normal phenotype. The variability of  the phenotype was 
shown to be determined by a genetic element that is approximately 9 cM away from the Col2a1 locus. 
Our linkage analysis revealed that the CHD-causing locus is linked with the mutant IIA locus on chromo-
some 15 and originates from the 129S1/SvImJ allele in the R1 ES cell line. Upon crossing over with the 
allele from C57BL/6N, 129/SvEv, or ICR, the phenotype was lost. Our fine mapping using a congenic set 
of  C57-IIA−/− mice narrowed down the candidate region to 1.2 Mb (from chr15:102.29–103.49 Mb) and 
showed a recessive and simple Mendelian inheritance pattern of  the new genetic locus. A frameshift muta-
tion of  the Hnrnpa1 gene was identified to cause CHD phenotypes in mouse. Hnrnpa1 mRNA was almost 
absent in the Hnrnpa1ct/ct homozygous mutant, caused by the nonsense-mediated decay of  the transcripts’ 
Figure 7. KO of Hnrnpa1 impaired cardiomyocyte differentiation in vitro. (A) Hnrnpa1 KO 1 and KO 2 mESC lines were established by the CRISPR/Cas9 meth-
od. PCR products of exon 6 in Nkx2.5-EGFP-mESCs (lane 2, 3 and 5, 425 bp), Hnrnpa1 KO 1 (lane 4, 343 bp), and KO 2 (lane 6, 404 bp) were shown. Sequencing 
and blasting results demonstrate that 82-bp and 21-bp fragments of exon6 of Hnrnpa1 are deleted in Hnrnpa1 KO 1 and KO 2, respectively, by the CRISPR/
Cas9 technique. (B) For each group, in vitro differentiation was performed 3 times. mESCs were induced into cardiomyocytes. Embryonic bodies (EBs) formed 
2–3 days later. Loosely aggregated EBs were observed in Hnrnpa1 KO 1 and KO 2 groups (day 3–5). After attachment of EBs to the plate at day 6, outgrowths 
were impaired in both Hnrnpa1 KO 1 and KO 2 groups (day 7–day 9). Scale bar: 200 μm. (C) The percentage of Nkx2.5-EGFP–positive cells was analyzed by flow 
cytometry at day 7. Compared with the Nkx2.5-EGFP-mESC group, significantly reduced Nkx2.5-EGFP–positive cells were detected in both Hnrnpa1 KO 1 and 
KO 2 groups. Data in C are presented as mean ± SD, with n = 3 per group. **P < 0.01; ***P < 0.001 by unpaired 2-tailed t tests with Bonferroni correction.
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Figure 8. HNRNPA1 mutations in human congenital heart disease patients. (A) Mutations in 2 trio families. (B) Both Gly203 and Gly283 locate in the con-
served region of HNRNPA1 protein. CHD, congenital heart disease.
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machinery. Loss of  Hnrnpa1 expression leads to cardiac looping defects at E9.5, VSD and PTA at E13.5, 
and embryonic lethality at P0, or VSD/DORV in some rare cases. Hnrnpa1 is expressed in both FHF and 
SHF cardiac lineages during the cardiac crescent stage; however, Hnrnpa1 was only strongly maintained in 
SHF progenitors after heart tube formation in mouse embryos. Hnrnpa1 mutant mice have reduced Hnrn-
pa1 mRNA expression in a dose-dependent manner. The Hnrnpa1ct/ct mutation leads to altered expression 
pattern of  Nkx2.5 and Isl1.
Hnrnpa1 is involved in the development of  both the FHF and SHF. The heart originates from two different 
lineages, the FHF and the SHF. The earliest differentiated cardiomyocytes are generated in the ALPM 
(37, 38). Then, the differentiated myocardial cells, which are situated in the lateral splanchnic mesoderm, 
form the cardiac crescent, whereas the SHF-derived cardiac progenitors are localized medially and dor-
sally to these differentiated myocardial cells. Whole-mount in situ analysis demonstrates that Hnrnpa1 
mRNA is expressed within ALPM in the pre–cardiac crescent stage. During the cardiac crescent stage, 
Hnrnpa1 is strongly expressed in both the splanchnic mesoderm and differentiated myocardium. Reduc-
tion of  Nkx2.5-expressing myocardium (Figure 5, C and D) and loss of  Isl1-expressing tissues around the 
pharyngeal region in Hnrnpa1ct/ct homozygous mutants (Figure 6, C and D) support the role of  Hnrnpa1 
in both FHF and SHF lineages during early cardiac development. Similar to loss of  Nkx2.5-expressing 
myocardium, the reduced Nkx2.5-expressing population was also observed during the differentiation of  
Hnrnpa1-KO mESCs into cardiomyocytes (Figure 7C). After the formation of  primitive heart tube, Hnrnpa1 
maintains strong expression in the splanchnic mesoderm but not in the heart tube. Though the primitive 
heart tube forms in Hnrnpa1ct/ct homozygous mutants, the elongation and looping process of  the heart tube 
was not initiated till E8.5 (9 somite pairs) (Figure 5, E and F). A truncated and incomplete looped heart 
tube was detected at E9.5 (25 somite pairs; Figure 5, I and J). Markedly reduced Isl1 expression (Figure 6, 
K and L) and restricted Nkx2.5-expressing domain (Figure 5, K and L) in the splanchnic mesoderm indicate 
SHF-derived cardiac defects. Thus, Hnrnpa1 may be essential for both FHF and SHF lineages at the cardiac 
crescent stage but plays a major role in the SHF after heart tube formation.
Hnrnpa1ct/ct mutation leads to perturbations of  cardiac transcription networks and multiple signaling pathways, 
including the FGF, BMP, and Notch pathways, in the SHF. During cardiac looping morphogenesis, SHF pro-
genitors are recruited toward the distal OFT and venous region of  the elongating heart tube, which finally 
contribute to the development of  the OFT, right ventricle, both atria, and a small portion of  the left ventri-
cle (31, 39). Proper development of  the SHF is essential for both remodeling of  the OFT and cardiac sep-
tum formation. Impaired development of  the SHF has been associated with OFT alignment defects, such 
as DORV, PTA, TGA, and TOF (40–43). Other evidence shows that disturbance of  regulatory networks in 
the SHF leads to a variety of  VSDs at the arterial pole and causes a series of  ASDs or AVSDs at the venous 
pole (44–49). Thus, the VSD, PTA, and DORV displayed in the Hnrnpa1ct/ct homozygous mutants seem to 
be associated with impaired SHF development.
The development of  the SHF is regulated by complex transcription networks. qRT-PCR results 
demonstrate that the expression levels of  several cardiac transcription factors, including Isl1, Nkx2.5, and 
Tbx1, decreased significantly in the SHF of  Hnrnpa1ct/ct homozygous mutants (Figure 4C). All of  these 
transcription factors have been implied in the pathogenesis of  CHDs. Failure of  cardiac looping morpho-
genesis has been observed in both Isl1- and Nkx2.5-null mouse models (31, 50). Specific inactivation of  
Nkx2.5 in the SHF leads to complete penetrance of  OFT defects, and PTA is the major phenotype (30). 
Nkx2.5 mutations have been associated with a broad spectrum of  human CHDs, including ASD, AVSD, 
DORV, TGA, TOF, VSD, and truncus arteriosus (7, 51–54). Tbx1 is also proposed as a major candidate for 
Table 2. Prediction of the function of the two human HNRNPA1 mutants
Mutation Taster (score) PolyPhen 2 (score) SNPdryad (score) FATHMM MetaSVM MetaLR CADD (score)
p. Gly283Arg 
rs375259222
Disease causing–splice site changes,  
protein feature affected (0.987)
D (0.996) D (0.96) D D D D (17.9)
p. 203-204 del Gly Disease causing–protein  
feature affected (0.999)
– – – – – –
All programs predicted the variant (p. Gly283Arg) of rs375259222 as possibly damaging. Mutation Taster predicted the de novo mutation of p. 203–204 del 
Gly as possibly damaging. D, possibly damaging.
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del22q11.2 deletion syndrome (or DiGeorge syndrome), characterized by serious craniofacial and cardio-
vascular defects, including TOF and common arterial trunk (CAT) (6, 55). Tbx1 heterozygous null mice 
also display a high incidence of  OFT anomalies (56).
Interrupted signaling pathways in the SHF are also suggested to be involved in the pathogenesis of  
CHDs. qRT-PCR results also showed that Hnrnpa1ct/ct homozygous mutation impairs multiple signaling 
pathways, such as FGF, BMP, and Notch pathways (Figure 4C). FGF signaling has been proved to regulate 
the proliferation of  SHF cardiac progenitors. Inactivation of  Fgf8 in the AHF leads to reduced prolifera-
tion and excess cell death in the pharyngeal mesoderm and adjacent tissues (57, 58). Impaired septation, 
rotation, and alignment of  the OFT, including PTA, TGA, and DORV, as well as interrupted cardiac septal 
and valve development, such as VSD, have been observed in Fgf8-hypomorphic mice (59). Ablation of  
mesodermal Fgf8 with MesP1Cre leads to hypomorphic OFT and right ventricle, which can be significantly 
exacerbated by compound inactivation of  mesodermal Fgf10 (60). BMP signaling has been proposed to 
inhibit FGF signaling, and the balance between FGF and BMP signaling is essential for regulation of  
proliferation and differentiation in the SHF cardiac progenitors (61, 62). In mouse embryos, conditional 
deletion of  Bmpr1a via Isl1-Cre leads to CHDs, including ASD, VSD, PTA, and underdeveloped valves (63). 
Specific inactivation of  Bmpr1a from venous pole SHF also leads to hypoplasia of  the DMP precursors, 
failure of  the DMP formation, and ostium primum defects, which contribute to the pathogenesis of  AVSD 
(64). Deletion of  Acvr1 in the AHF can cause VSD and aorticopulmonary (AP) trunk septation defects (65). 
Notch signaling also plays a vital role during cardiac development, and absence of  Notch ligand Jagged1 
(Jag1) in the SHF causes severe cardiac anomalies, such as DORV and VSD (66).
Similar to these cardiac defects mentioned above, failure of  looping morphogenesis, impaired cardiac 
septum formation (VSD), and OFT anomalies (PTA and DORV) have been observed in Hnrnpa1ct/ct homo-
zygous mutants (Figure 2 and Supplemental Figure 5). qRT-PCR results demonstrated that expression 
levels of  Acvr1, Bmpr1a, Fgf8, Isl1, Jag1, Nkx2.5, and Tbx1 decrease significantly in the SHF of  Hnrnpa1ct/ct 
homozygous mutants (Figure 4C). Thus, Hnrnpa1 might play an upstream regulatory role during cardiac 
development. Hnrnpa1ct/ct homozygous mutation leads to dysregulation of  multiple cardiac transcription 
factors and signaling pathways in the SHF, which further contributes to the pathogenesis of  CHDs, includ-
ing OFT malalignment and cardiac septal defects displayed in Hnrnpa1ct/ct mutant mice.
After the formation of  the primitive heart tube, Hnrnpa1 maintains its expression in the SHF but not 
in the heart tube. In Hnrnpa1ct/ct homozygous mutants, though the expression level of  Nkx2.5 decreased 
dramatically in the SHF region, no significant difference was detected in the heart tube by qRT-PCR. 
Consistent with this, no significant variations of  Mlc2a, Mlc2v, Myocd, and SRF expression in the heart 
tubes or Mef2c expression in both heart tubes and the SHF tissues could be observed (Figure 4C). During 
smooth muscle differentiation, hnRNP A1 has been suggested as a transcription factor to activate the 
transcription of  MEF2c, SRF, and Myocd (14). Thus, Hnrnpa1 may have different regulatory role during 
cardiomyocytes differentiation.
All above results demonstrate that at E9.5 Hnrnpa1 has a major regulatory role in the SHF. hnRNP 
A1 is usually considered as a repressor for alternative splicing, which plays an important role in modula-
tion of  exon skipping. hnRNP A1 can also work as a transcription factor to activate the transcription of  
downstream targets. In addition, hnRNP A1 has been reported to regulate the nuclear export, stability, and 
alternative translation of  the mRNA (9–13). Thus, hnRNP A1 may regulate downstream cardiac genes via 
these different manners. However, the detailed mechanisms of  how hnRNP A1 regulates these genes are 
still largely unknown.
Hnrnpa1ct/ct homozygous mutation may impair the development of  the DM and SAN progenitors. Whole-mount 
in situ hybridization and section analyses show impaired development of  the DM and markedly reduced Isl1 
mRNA in this region (Figure 6, M and N). The DMP, which represents the protrusion of  discrete mesenchy-
mal cells from the DM toward the atrial cavity, is derived from the Isl1-expressing SHF lineage and is associat-
ed with atrioventricular septal defects (46, 47, 67, 68). DMP resides as an integral component of  the atrioven-
tricular mesenchymal complex and undergoes mesenchymal-to-myocardial transition in an Nkx2.5-dependent 
manner (46). The DM defects and altered Isl1 and Nkx2.5 expression pattern may disturb the formation of  
DMP and, thus, impair atrioventricular septal development in Hnrnpa1ct/ct homozygous mutants.
A previous study has indicated the important roles of  Isl1 and Nkx2.5 in SAN development. Isl1 is 
expressed in the majority of  cardiac pacemaker cells throughout the developmental of  SAN. Lineage tracing 
and specific ablation of  Isl1 in SAN lineage indicate that Isl1 is essential for the maintenance, proliferation, 
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and function of  SAN cells (69). Transcriptome and ChIP analysis demonstrated that Isl1 is involved in 
the expression regulation of  several genes associated with SAN development, such as Ank2 and Tbx3 (69). 
Around E9.5, the earliest SAN progenitors, a Isl1- and Tbx18-positive but Nkx2.5-negative population, were 
detected in the right lateral junction between the atria and sinus horn (36, 70). Isl1 expression in this region 
is absent in the Hnrnpa1ct/ct mutants (Figure 6, I and J), implicating the loss or deficient development of  
SAN progenitors. Nkx2.5 suppresses the formation of  SAN to establish the boundary between atrial myo-
cardium and SAN progenitors, which can be antagonized by Shox2 (71–73). A recent model shows that 
Nkx2.5 directly binds to an enhancer of  Isl1 and inhibits its transcriptional activity, which is required for the 
determination of  myocytes subtype identity (74). Hnrnpa1ct/ct homozygous mutation leads to posterior exten-
sion of  the Nkx2.5-expressing domain in the sinus horns at E8.5 (Figure 5, E and F) and expansion of  the 
Nkx2.5-expressing atria at E9.5 (Figure 5, I and J), thereby suggesting that the loss of  Isl1 expression in SAN 
progenitors may be associated with ectopic expression of  Nkx2.5 in the caudal venous pole. Thus, Hnrnpa1 
may play an essential role upstream of  Nkx2.5 and Isl1 to regulate the formation of  SAN.
Hnrnpa1 mutations contribute to CHDs. In our mouse model, CHDs, including incomplete looped heart 
tube at E9.5, VSD and PTA at E13.5, and VSD and DORV at P0, were only detected in the Hnrnpa1ct/ct 
homozygous mutants, while no obvious cardiac defect was observed in the heterozygous mutants. The 
number of  heterozygous mutant newborns also approximated the expected value. According to a recent 
study, muscle development was analyzed in the Hnrnpa1-null mouse line (24). Though the CHD phenotypes 
were not analyzed, significantly higher heart rates and systolic pressures were detected in E18.5 Hnrnpa1 
heterozygous null mice. Mouse exon array tests demonstrated that the expression pattern of  multiple mus-
cle-related genes was affected in the heterozygous mutant E18.5 hearts. The alternative splicing pattern of  
several muscle development–related genes, including Mef2c, Lrrfip1, Usp28, and Abcc9 was also changed, 
with a significantly lower full length/truncated transcripts ratio (24). These results indicated that both het-
erozygous and homozygous mutations of  Hnrnpa1 might have a role in the pathogenesis of  CHDs.
Two heterozygous rare mutations of  HNRNPA1 in human CHDs were also detected. We sequenced 
the human HNRNPA1 gene in 273 Chinese CHD trio probands and 225 sporadic Pakistani nonsyndrom-
ic CHD patients and discovered one rare inherited missense mutation and one de novo indel heterozy-
gous nonsynonymous variant; both of  these two cases mainly present the VSD phenotype with some 
additional complex heart phenotypes (Figure 8 and Supplemental Table 3). All this evidence supports 
the important role of  hnRNP A1 in cardiac development in both mice and human. Mutations associated 
with CHDs have been identified in at least 15 transcription factor genes (e.g., NKX2-5, GATA4, ILS1, and 
HAND2); 17 receptors, ligands, and signaling genes (e.g., ACVR2B, NOTCH1, and SMAD6); and 5 struc-
tural protein genes (e.g., ACTC and ELN) (1, 5). More recently, mutations in cilia and cilia-transduced 
cell signaling pathway genes have been identified by using unbiased screening ethylnitrourea-mutagen-
ized mice (75). Most of  these known genes for CHDs are involved in the altered levels of  developmental 
signaling molecules during cardiogenesis. However, an important role of  the RNA-binding protein in 
embryonic heart development is suggested.
The human HNRNPA1 encodes a full-length 372–amino acid protein (accession NP_112420.1) and a 
truncated 320–amino acid isoform (accession NP_002127.1). Similar to the Hnrnpa1ct/ct mutant mice, VSDs 
were also observed in human CHD patients with HNRNPA1 mutations. However, unlike the Hnrnpa1ct/ct 
mutant mice, humans with rare HNRNPA1 mutations did not display OFT defect phenotypes: PTA or 
DORV. The phenotypic heterogeneity may be underpinned by the facts that the Hnrnpa1ct/ct mutation is 
located in the RRM domain, even though both mutations found in the human samples are located outside 
this domain (at the 203–amino acid and 283–amino acid positions, accession NP_112420.1), and that both 
of  the human sample sets were found in live-born CHD patients with heterozygous mutations, suggesting 
that homozygous mutations might have caused more severe nonviable phenotypes, which were therefore not 
presented. Because the majority of  Hnrnpa1ct/ct mice died before birth, the 2 P0 mice in our samples were a 
rarity. It was noted that the missense rare variant was inherited from the mother of  one of  the patients, who 
had a nonreported cardiac phenotype. To our knowledge, CHDs sometimes reveal incomplete penetrance, 
and some mild CHDs can be self-corrected, thus becoming undetected in adulthood.
Conclusion. In conclusion, mutations in the Hnrnpa1 gene cause CHDs in both humans and mice. 
Hnrnpa1 is critical for both the FHF and SHF during early cardiac development. However, in later stages, 
Hnrnpa1 only has a major role in the SHF. Loss of  Hnrnpa1 in the SHF leads to dysregulation of  cardiac 
transcription factors, including Isl1, Nkx2.5, and Tbx1, as well as signaling pathways, such as the BMP, 
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FGF, and Notch pathways. Thus, CHDs can be caused by impaired development of  both the FHF and 
SHF lineages. This study provides insights into the mechanism by which Hnrnpa1 becomes involved in the 
cardiac development.
Methods
Animals. Three congenic mouse lines were established by repeatedly backcrossing the IIA+/− mutant mice to 
C57BL/6N, 129/SvEv, and ICR wild-type mice to obtain IIA+/− mutants with homogenous backgrounds. 
The IIA−/− mutants generated from the 3 mouse lines were named C57-IIA−/−, 129-IIA−/−, and ICR-IIA−/−, 
respectively. Construction of  mouse lines, collection of  embryos, and genotyping were performed as 
described in the supplemental materials (Supplemental Methods and Supplemental Figures 1–5 and 9).
Identification of  the CHD-causing genetic locus. After collection of  pedigrees, the CHD-causing genetic 
locus was searched by genome-wide linkage mapping, fine mapping, and high-throughput targeted sequenc-
ing and finally confirmed by Sanger sequencing, as described in the Supplemental Methods. All primers 
used for genotyping are listed in Supplemental Table 5.
Characterization of  CHDs in Hnrnpa1 mutant mice by histological and OPT analyses. The E13.5 embryos 
were sectioned and then stained with hematoxylin and eosin. OPT was performed for P0 mice (76). See the 
Supplemental Methods for further details.
Whole-mount in situ hybridization. Digoxigenin-labeled riboprobes, anti-digoxigenin-AP antibody 
(11093274910; MilliporeSigma), and BM Purple reagent (11442074001; Roche) were used for whole-
mount in situ hybridization, as described in the Supplemental Methods.
qRT-PCR. cDNA generated from total RNA of  wild-type embryos and heterozygous and homozygous 
mutants was subjected to SYBR Green-based real-time PCR analysis, as described in the Supplemental 
Methods. All qRT-PCR primers are listed in Supplemental Table 6.
Western blot analysis. Mouse embryos were dissected at E9.5 to analyze the expression level of  hnRNP 
A1. β-Actin was used as the loading control. Primary antibodies used were anti-mouse hnRNP A1 (sc-
32301; Santa Cruz) and anti–β-actin (A2228; MilliporeSigma). The blots were detected using chemilumi-
nescence, as described in the Supplemental Methods.
Cardiac stem cell differentiation into cardiomyocytes in vitro. CRISPR/Cas9 was used to KO Hnrnpa1 
in Nkx2.5-EGFP-mESCs (E14.RP11-88L12.Nkx2-5-EmGFP from MMRRC). Target and off-target 
primers are listed in Supplemental Table 7. These cells were differentiated into cardiomyocytes in 
vitro, and the Nkx2.5-EGFP–positive percentage was analyzed by flow cytometry, as described in the 
Supplemental Methods.
Screen of  HNRNPA1 variants in human patients. 273 Chinese nonsyndromic CHD patients and 225 spo-
radic Pakistani CHD patients were recruited. We also sequenced 300 Chinese normal individuals to ensure 
that the mutation was absent in the normal subjects (Supplemental Table 3 and 4). The phenotype of  CHDs 
and genotyping analysis were performed as described in the Supplemental Methods.
Statistics. NPL was calculated using Simwalk2. The NPL_ALL and BLOCK statistics (for recessive 
mode) were selected to evaluate the significance of  the reported linkage. TDT analysis using 40 markers 
was performed at E9.5 and P0. P < 0.001 (Figure 1, A and B) was considered significant. Significant 
differences in penetrance of  the CHD phenotypes among Hnrnpa1ct/ct, Hnrnpa1+/ct, and Hnrnpa1+/+ mice 
at selected time points were determined using Fisher’s exact test (P < 0.001 was considered signifi-
cant). For qRT-PCR and Western blot analyses, F test was performed first. Statistical differences were 
then determined using the unpaired Student’s t test (2-tailed P value, either equal or unequal variances 
depending on F test). Figures were generated using GraphPad Prism 6 software. P < 0.0167 (Figure 4, 
A and B, and Figure 7C) or P < 0.00111 (Figure 4C) was considered significant after Bonferroni correc-
tions. Otherwise, P values of  less than 0.05 were considered significant. Graphs represent mean ± SD.
Study approval. The mouse study was approved by the Committee on the Use of  Live Animal in 
Teaching and Research, University of  Hong Kong (no. 1264-06, 3598-15). All mice were housed in envi-
ronmentally controlled rooms in the Laboratory Animal Unit. Written informed consent was obtained 
from patients’ parents or guardians prior to inclusion in the study. The study protocols conformed to the 
ethical guidelines of  the 1975 Declaration of  Helsinki and were approved by the local ethics committee 
of  the National Research Institute for Family Planning, Beijing, China (IRB no. 20101015), the Univer-
sity of  Karachi (ref. no. KIBGE/ICE/35046/Sc/20/03/2007), and the University of  Hong Kong (IRB 
no. UW 13-550).
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